Biofarm (FRA:H3D) Moat Score: 0/10 (As of Jul. 11, 2026)


FRA:H3D Biofarm SA FRA:H3D
69 GF Score
Price €0.24
GF Value €0.15
! 6 Warning Signs
View Full Analysis

What is Biofarm Moat Score?

Biofarm has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Biofarm has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biofarm might have No Moat - No discernible moat.

Biofarm  (FRA:H3D) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biofarm Moat Score Related Terms

FRA:H3D
69GF Score
Biofarm SA FRA:H3D
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofarm (FRA:H3D) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of €0.24 is trading 60.7% above its estimated GF Value™ of €0.15.

Key valuation signals for FRA:H3D:

  • Moat Score: 0
  • GF Value™: €0.15 vs. price of €0.24 (60.7% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the FRA:H3D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Other Exchanges BIO:Romania
Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for FRA:H3D

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.15
GF Value